Presentation is loading. Please wait.

Presentation is loading. Please wait.

Jessica J. Lin, MD, Ginger Y

Published byMervin Fields Modified over 5 years ago

Similar presentations

Presentation on theme: "Jessica J. Lin, MD, Ginger Y"— Presentation transcript:

1 Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases 
Jessica J. Lin, MD, Ginger Y. Jiang, MD, Nencyben Joshipura, MD, Jennifer Ackil, NP, Subba R. Digumarthy, MD, Sandra P. Rincon, MD, Beow Y. Yeap, ScD, Justin F. Gainor, MD, Alice T. Shaw, MD, PhD  Journal of Thoracic Oncology  Volume 14, Issue 4, Pages (April 2019) DOI: /j.jtho Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Tumor responses to alectinib. (A) Maximal percent change in target intracranial lesions from baseline in patients with measurable central nervous system disease. (B) Maximal percent change in target lesions from baseline in patients with measurable overall disease. Patients unevaluable for response or with nonmeasurable disease are not shown. Dotted horizontal line shows the 30% threshold for partial response. Asterisk indicates stable disease. Dot indicates partial response. ALK, ALK receptor tyrosine kinase; TKI, tyrosine kinase inhibitor. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Representative intracranial responses to alectinib in patients. (A) Axial postcontrast T1-weighted magnetic resonance imaging of response in a patient (patient 1 [see Supplementary Table 1]) who previously received crizotinib and ceritinib. Brain imaging pursued for headaches revealed new metastatic lesions (the largest measured 4.9 cm, with edema and midline shift). The patient declined neurosurgical intervention. He began taking steroids and alectinib, 600 mg twice daily, resulting in complete resolution of the headaches and a marked radiographic response (a 70% intracranial and 67% extracranial tumor reduction as the best response). Steroid therapy was discontinued within 3 weeks without recurrent headaches. The patient received alectinib for more than 2 years, with a CNS duration of response of 17 months. (B) Axial fluid-attenuated inversion recovery magnetic resonance imaging of the response to alectinib in a previously untreated patient (patient 6 [see Supplementary Table 1]) with symptomatic large brain metastases. This patient started taking steroids and first-line alectinib with clinical and radiographic response (a 75% intracranial tumor reduction and extracranial complete response). Steroids were completely tapered within 2 months of alectinib therapy. At data cutoff, she was continuing to take alectinib beyond 14 months with an ongoing response. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Duration of treatment. Arrows indicate patients continuing on alectinib at data cutoff. Triangles indicate the time points at which a central nervous system (CNS) response was first observed. Circles represent the time points of CNS disease progression. Asterisk indicates a patient whose disease was unevaluable for CNS response. ALK, ALK receptor tyrosine kinase; TKI, tyrosine kinase inhibitor. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Jessica J. Lin, MD, Ginger Y"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,
Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Recent Advances in Targeting ROS1 in Lung Cancer

Recent Advances in Targeting ROS1 in Lung Cancer
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Alexey Surov, MD, Michael Hainz, MD, Malte Kornhuber, MD 

Alexey Surov, MD, Michael Hainz, MD, Malte Kornhuber, MD 
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S
High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib  Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib  Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,

Similar presentations

Ads by Google